ArticleLupus science & medicine2026

Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus.

Elsa Martins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.